on June 12, 2003
Published online before print June 12, 2003, doi: 10.1161/01.ATV.0000081635.96290.D3
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on February 12, 2003
Accepted on May 19, 2003
Paraoxonase Activity, But Not Haplotype Utilizing The Linkage Disequilibrium Structure, Predicts Vascular Disease
Gail P. Jarvik *;
From the Departments of Medicine (Division of Medical Genetics) (G.P.J., R.J.R., R.J., V.H.B., S.M., C.E.F.), Epidemiology (G.P.J.), Genomic Sciences (G.P.J., C.C., M.R., D.N., C.E.F.), Neurology (G.D.S.), and Biostatistics (P.J.H.), University of Washington, and the Puget Sound Veterans Affairs Health Care System (T.S.H., G.D.S.), Seattle, Wash.
* To whom correspondence should be addressed. E-mail: pair{at}u.washington.edu.
Objective--The effects of paraoxonase (PON1) activity and of genetic variation in the PON1 promoter and coding region on carotid artery disease (CAAD) were investigated.
Methods and Results--We identified functional promoter polymorphisms and examined their effects in a cohort with and without CAAD. We used the full sequences in 23 white subjects to determine the linkage disequilibrium (LD) structure of the PON1 region and to direct the grouping of haplotypes for disease association testing. There are several discrete regions of the PON1 gene with strong local LD, but the useful levels of LD do not extend across the entire gene. Indeed, PON1-162/-108/55/192 haplotype did not predict additional variation in PON1 activities compared with the 4 genotypes separately. PON1 hydrolysis activity predicted CAAD status, but this was not attributable to the promoter or coding region polymorphisms or haplotype or to the effects of smoking or statin use on PON1 activity.
Conclusions--PON1 does not have LD across the gene, and use of haplotypes in association studies should consider the LD structure. PON1 activity predicts CAAD, yet 4 functional polymorphisms do not. Additional investigations of genetic and environmental factors that influence PON1 activity as a risk factor for vascular disease are warranted.
This article has been cited by other articles:
 |
|
 |
|
  B. Thyagarajan, D. R. Jacobs Jr., J. J. Carr, O. Alozie, M. W. Steffes, P. Kailash, J. H. Hayes, and M. D. Gross Factors Associated with Paraoxonase Genotypes and Activity in a Diverse, Young, Healthy Population: The Coronary Artery Risk Development in Young Adults (CARDIA) Study Clin. Chem., April 1, 2008; 54(4): 738 - 746. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Frikke-Schmidt, B. G. Nordestgaard, G. B. Jensen, R. Steffensen, and A. Tybjaerg-Hansen Genetic Variation in ABCA1 Predicts Ischemic Heart Disease in the General Population Arterioscler. Thromb. Vasc. Biol., January 1, 2008; 28(1): 180 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Van Eck, M. Hoekstra, R. B. Hildebrand, Y. Yaong, D. Stengel, J. K. Kruijt, W. Sattler, U. J.F. Tietge, E. Ninio, T. J.C. Van Berkel, et al. Increased Oxidative Stress in Scavenger Receptor BI Knockout Mice With Dysfunctional HDL Arterioscler. Thromb. Vasc. Biol., November 1, 2007; 27(11): 2413 - 2419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L Rainwater, M. C Mahaney, J. L VandeBerg, and X. L. Wang Vitamin E dietary supplementation significantly affects multiple risk factors for cardiovascular disease in baboons Am. J. Clinical Nutrition, September 1, 2007; 86(3): 597 - 603. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Gaidukov and D. S. Tawfik The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity J. Lipid Res., July 1, 2007; 48(7): 1637 - 1646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Goode, J. D. Potter, W. R. Bamlet, D. N. Rider, and J. Bigler Inherited variation in carcinogen-metabolizing enzymes and risk of colorectal polyps Carcinogenesis, February 1, 2007; 28(2): 328 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Carty, P. Heagerty, K. Nakayama, E. C. McClung, J. Lewis, D. Lum, E. Boespflug, C. McCloud-Gehring, B. R. Soleimani, J. Ranchalis, et al. Inflammatory Response After Influenza Vaccination in Men With and Without Carotid Artery Disease Arterioscler. Thromb. Vasc. Biol., December 1, 2006; 26(12): 2738 - 2744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Gaidukov, M. Rosenblat, M. Aviram, and D. S. Tawfik The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux J. Lipid Res., November 1, 2006; 47(11): 2492 - 2502. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. L. Stevens, C. Rodriguez, A. L. Pavluck, M. J. Thun, and E. E. Calle Association of Polymorphisms in the Paraoxonase 1 Gene with Breast Cancer Incidence in the CPS-II Nutrition Cohort. Cancer Epidemiol. Biomarkers Prev., June 1, 2006; 15(6): 1226 - 1228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Marchegiani, M. Marra, L. Spazzafumo, R. W. James, M. Boemi, F. Olivieri, M. Cardelli, L. Cavallone, A. R. Bonfigli, and C. Franceschi Paraoxonase activity and genotype predispose to successful aging. J. Gerontol. A Biol. Sci. Med. Sci., June 1, 2006; 61(6): 541 - 546. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Carlson, P. J. Heagerty, T. S. Hatsukami, R. J. Richter, J. Ranchalis, J. Lewis, T. J. Bacus, L. A. McKinstry, G. D. Schellenberg, M. Rieder, et al. TagSNP analyses of the PON gene cluster: effects on PON1 activity, LDL oxidative susceptibility, and vascular disease J. Lipid Res., May 1, 2006; 47(5): 1014 - 1024. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Shih, H. R. Kast-Woelbern, J. Wong, Y.-R. Xia, P. A. Edwards, and A. J. Lusis A role for FXR and human FGF-19 in the repression of paraoxonase-1 gene expression by bile acids J. Lipid Res., February 1, 2006; 47(2): 384 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Erlich, K. L. Lunetta, L. A. Cupples, M. Huyck, R. C. Green, C. T. Baldwin, L. A. Farrer, and for the MIRAGE Study Group Polymorphisms in the PON gene cluster are associated with Alzheimer disease Hum. Mol. Genet., January 1, 2006; 15(1): 77 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Rozek, T. S. Hatsukami, R. J. Richter, J. Ranchalis, K. Nakayama, L. A. McKinstry, D. A. Gortner, E. Boyko, G. D. Schellenberg, C. E. Furlong, et al. The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status J. Lipid Res., September 1, 2005; 46(9): 1888 - 1895. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Chen, W. Chan, S. Wallenstein, G. Berkowitz, and J. G. Wetmur Haplotype-Phenotype Relationships of Paraoxonase-1 Cancer Epidemiol. Biomarkers Prev., March 1, 2005; 14(3): 731 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Nguyen and D.-E. Sok Preferential inhibition of paraoxonase activity of human paraoxonase 1 by negatively charged lipids J. Lipid Res., December 1, 2004; 45(12): 2211 - 2220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kontush, E. C. de Faria, S. Chantepie, and M. J. Chapman Antioxidative Activity of HDL Particle Subspecies Is Impaired in Hyperalphalipoproteinemia: Relevance of Enzymatic and Physicochemical Properties Arterioscler. Thromb. Vasc. Biol., March 1, 2004; 24(3): 526 - 533. [Abstract] [Full Text]
|
|
|
|
|
|
B. N. La Du Future Studies of Low-Activity PON1 Phenotype Subjects May Reveal How PON1 Protects Against Cardiovascular Disease Arterioscler. Thromb. Vasc. Biol., August 1, 2003; 23(8): 1317 - 1318. [Full Text] [PDF]
|
|